The role of BDNF/PI3K/AKT/Nrf2 signaling in nicotine's protective effects against MPTP-induced Parkinson's disease.
Level 5 - mechanism / opinion, no new human data
Animal model and ex vivo laboratory experiment.
PubMed 41077168 · doi:10.1016/j.neulet.2025.138412
What was done
Male BALB/c mice were divided into control, nicotine, MPTP, and MPTP + nicotine treatment groups to evaluate neuroprotection in a toxin-induced model of Parkinson's disease. Histological staining was used to assess neuronal pyknosis and tyrosine hydroxylase-positive dopaminergic neurons in the substantia nigra. Biochemical assays evaluated oxidative markers (malondialdehyde, lactate dehydrogenase, lactate/pyruvate ratio), mitochondrial complex I activity, and antioxidant enzymes (SOD, CAT, GPx, GR). Western blotting measured phosphorylated PI3K, AKT, Nrf2, Bcl-2, Bax, and Bad, alongside BDNF quantification and ex vivo assays testing alpha7 nicotinic acetylcholine receptor involvement.
What was found
Nicotine administration attenuated MPTP-induced neuronal pyknosis and preserved tyrosine hydroxylase-positive dopaminergic neurons. It reduced malondialdehyde, lactate dehydrogenase, and the lactate/pyruvate ratio, while restoring complex I, SOD, CAT, GPx, and GR enzyme activities. Nicotine reversed MPTP-induced suppression of phosphorylated PI3K, AKT, and Nrf2, increased anti-apoptotic Bcl-2, decreased pro-apoptotic Bax and Bad, and restored BDNF expression via alpha7 nicotinic acetylcholine receptor activation. The abstract does not provide exact numerical values, effect sizes, or confidence intervals.
Why it matters
This study outlines a mechanistic pathway (alpha7 nAChR-mediated BDNF/PI3K/AKT/Nrf2 signaling) that may explain epidemiological links between nicotine exposure and reduced Parkinson's disease risk, highlighting downstream targets for drug development.
Limits
The findings are restricted to an acute MPTP mouse model and ex vivo tissue, which do not fully replicate human chronic progressive Parkinson's disease. Exact animal numbers, dosing regimens, timing of interventions, and statistical effect sizes are omitted from the abstract. Nicotine carries addiction and toxicity liabilities that preclude direct clinical application without selective pathway targeting.
Cited by
- supports Nicotine protects dopaminergic neurons and cholinergic neurons despite raising blood pressure.